RiverVest Venture Partners β 2025 Investments
5 investments dated 2025 Β· listed companies and verified rows first Β· show all
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)Jacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)
Board seatJay W. SchmelterΒ· per SEC Form D
Co-investorsBroadview VenturesTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCS3 Ventures+1 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)Clifford J. Stocks(Director, Executive Officer)Kamal D. Puri(Executive Officer)Chris Russell(Executive Officer)Russ Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatJohn McKearnΒ· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesARCH Venture PartnersBering CapitalIntervest+3 more
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)David Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in
Board seatNiall O'DonnellΒ· per SEC Form D
Co-investorsOrbiMedRA CapitalUS Venture Partners
HealthtechPlymouth, US
John Pigott(Executive Officer, Director)Jenny Zeroni(Executive Officer)Dave Michaelson(Executive Officer)Kathy Leith(Executive Officer)Jill Schweiger(Executive Officer)Shelby Hautman(Executive Officer)
Board seatKaren SpilizewskiΒ· per SEC Form D
Co-investorsEndeavour VisionS3 Ventures
Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.
BiotechHealthtech
Co-investorsF-Prime CapitalNovartis Venture FundSanofi Venturesabrdn plcEQT Life Sciences
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.